• China's drug regulatory framework has undergone significant reforms, aligning more closely with international standards and practices.
• International collaboration, particularly with the US FDA, has facilitated the adoption of advanced regulatory science methodologies in China.
• The integration of real-world evidence and adaptive trial designs is crucial for accelerating drug approval while maintaining safety standards.
• Strengthening regulatory science capacity is essential for China to effectively respond to public health emergencies and foster pharmaceutical innovation.